तुलना करने के लिए मीट्रिक्स | BYSI | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधBYSIपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −7.0x | −2.7x | −0.5x | |
PEG अनुपात | −0.08 | 0.00 | 0.00 | |
क़ीमत/बुक | −1.9x | 3.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 8.4x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 95.4% | 50.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | −7.1% | 7.2% | अनलॉक करें |
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company’s lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.